The Trump administration is intensifying its investigations into the imports of semiconductors and pharmaceuticals, paving the way for potential new tariffs. This move, described as a major step toward economic self-reliance, has raised concerns about the implications it may have on the pharmaceutical sector, including potential drug shortages and price hikes for consumers. Although Trump claims that tariffs on imported drugs will bring production back to the U.S., experts argue that these measures could exacerbate existing issues within the healthcare system. As probes into various sectors continue, the White House faces growing uncertainty and political risks, with strong reactions from global pharmaceutical companies and critics who warn that increased tariffs could lead to higher costs for patients. The administration is also considering exemptions related to the automotive industry, adding another layer of complexity to the ongoing trade discussions.